Novavax, Inc., (Nasdaq: NVAX) today announced positive top-line results from its Phase 1/2 clinical trial in older adults of its ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Novavax (NVAX) Releases Promising Data on NanoFlu Vaccine, Prompting Upgrade at CitiMarch 1, 2018 12:50 PM Novavax, Inc. : Novavax NanoFlu(TM) Vaccine Demonstrates Improved Immune Responses Compared to Egg-Based, High-Dose Flu Vaccine February 28, 2018 4:06 PM